First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.

Grünwald V, Rußwurm K, Eckert R, Seseke S, Standhaft D, Hegemann M, Baumann S, Brenneis H, Seidel M, Rau O, Schirrmacher-Memmel S, Hellmis E, Fieseler CF, Doehn C, Ziske C, Distelrath A, Marschner N, Ivanyi P, Herold M, Loehr BI, Lange C, Janitzky A, Bögemann M

Open source

DOI: 10.3390/cancers17243910
Published: 2025 Dec 7
Container: Cancers
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3390/cancers17243910,
  title = {First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.},
  author = {Grünwald V and Rußwurm K and Eckert R and Seseke S and Standhaft D and Hegemann M and Baumann S and Brenneis H and Seidel M and Rau O and Schirrmacher-Memmel S and Hellmis E and Fieseler CF and Doehn C and Ziske C and Distelrath A and Marschner N and Ivanyi P and Herold M and Loehr BI and Lange C and Janitzky A and Bögemann M},
  year = {2025},
  journal = {Cancers},
  doi = {10.3390/cancers17243910},
  url = {https://doi.org/10.3390/cancers17243910}
}

RIS

TY  - JOUR
TI  - First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.
AU  - Grünwald V
AU  - Rußwurm K
AU  - Eckert R
AU  - Seseke S
AU  - Standhaft D
AU  - Hegemann M
AU  - Baumann S
AU  - Brenneis H
AU  - Seidel M
AU  - Rau O
AU  - Schirrmacher-Memmel S
AU  - Hellmis E
AU  - Fieseler CF
AU  - Doehn C
AU  - Ziske C
AU  - Distelrath A
AU  - Marschner N
AU  - Ivanyi P
AU  - Herold M
AU  - Loehr BI
AU  - Lange C
AU  - Janitzky A
AU  - Bögemann M
PY  - 2025
JO  - Cancers
DO  - 10.3390/cancers17243910
UR  - https://doi.org/10.3390/cancers17243910
ER  -

APA

V, G., K, R., R, E., S, S., D, S., M, H., S, B., H, B., M, S., O, R., S, S., E, H., CF, F., C, D., C, Z., A, D., N, M., P, I., M, H., BI, L., C, L., A, J., & M, B. (2025). First-Line Treatment with Tivozanib for Metastatic Renal Cell Carcinoma in Real-World Settings Across Germany: Results of the Prospective, Non-Interventional, Post-Approval Study T-Rex.. Cancers. https://doi.org/10.3390/cancers17243910

Source records

pubmed · retrieved 2026-09-25T18:46:07.889Z